"Increasingly, medical oncologists work with multidisciplinary teams to diagnose and manage lung cancer cases. Interventional pulmonologists on these teams perform diagnostic workups, obtain tissue biopsies, and play a role in the timely diagnosis and staging of lung...
CAP Today: “Liquid biopsy is a reality in oncology today. It’s amazing how rapidly it has become the standard of care. And I think pathology labs everywhere are trying to adapt to it and make themselves ready for this new reality.” Read the...
“Availability of biomarker data early in the treatment process enables tumor boards to review cases more efficiently and to better understand treatment options.”
“Liquid biopsy really opens the possibility of a kind of real-time molecular analysis of the tumor to help inform treatment choices,” Dr. Burstein concluded.
China Television (CGTV) recently produced a story about Biodesix's recent agreement with Bioyong to bring a version of the VeriStrat test to China. The story includes an explanation of how VeriStrat works, from Dr. Gary Pestano....
“VeriStrat appears to be a robust assay and should be used for EGFR wild-type patients with squamous cell lung cancer,” says study author Glenwood D. Goss, MD, professor of medicine and an oncologist in the division of medical oncology at the University of Ottawa. Biodesix presented data relating to immunotherapy selection, afatinib efficacy.
Read the story in BizWest magazine
One News video
GenomeWeb story: Biodesix receives two positive coverage decisions for VeriStrat.